Abstract
Therapeutics designed to increase synaptic neurotransmitter levels by inhibiting neurotransmitter sodium symporters (NSSs) classify a strategic approach to treat brain disorders such as depression or epilepsy, however, the critical elementary steps that couple downhill flux of sodium to uphill transport of neurotransmitter are not distinguished as yet. Here we present modelling of NSS member neuronal GAT1 with the substrate γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter. GABA binding is simulated with the occluded conformation of GAT1 homodimer in an explicit lipid/water environment. Simulations performed in the 1-10 ns range of time elucidated persistent formation of halfextended minor and H-bridged major GABA conformations, referred to as binding and traverse conformations, respectively. The traverse GABA conformation was further stabilized by GAT1-bound Na+(1). We also observed Na+(1) translocation to GAT1-bound Cl- as well as the appearance of water molecules at GABA and GAT1-bound Na+(2), conjecturing causality. Scaling dynamics suggest that the traverse GABA conformation may be valid for developing substrate inhibitors with high efficacy. The potential for this finding is significant with impact not only in pharmacology but wherever understanding of the mechanism of neurotransmitter uptake is valuable.
Keywords: Binding and traverse conformation, neurotransmitter sodium symporter family, neuronal GABA symporter subtype, sodium symport.
Current Drug Discovery Technologies
Title:Sodium-Assisted Formation of Binding and Traverse Conformations of the Substrate in a Neurotransmitter Sodium Symporter Model
Volume: 11 Issue: 3
Author(s): Agnes Simon, Akos Bencsura, Laszlo Heja, Csaba Magyar and Julianna Kardos
Affiliation:
Keywords: Binding and traverse conformation, neurotransmitter sodium symporter family, neuronal GABA symporter subtype, sodium symport.
Abstract: Therapeutics designed to increase synaptic neurotransmitter levels by inhibiting neurotransmitter sodium symporters (NSSs) classify a strategic approach to treat brain disorders such as depression or epilepsy, however, the critical elementary steps that couple downhill flux of sodium to uphill transport of neurotransmitter are not distinguished as yet. Here we present modelling of NSS member neuronal GAT1 with the substrate γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter. GABA binding is simulated with the occluded conformation of GAT1 homodimer in an explicit lipid/water environment. Simulations performed in the 1-10 ns range of time elucidated persistent formation of halfextended minor and H-bridged major GABA conformations, referred to as binding and traverse conformations, respectively. The traverse GABA conformation was further stabilized by GAT1-bound Na+(1). We also observed Na+(1) translocation to GAT1-bound Cl- as well as the appearance of water molecules at GABA and GAT1-bound Na+(2), conjecturing causality. Scaling dynamics suggest that the traverse GABA conformation may be valid for developing substrate inhibitors with high efficacy. The potential for this finding is significant with impact not only in pharmacology but wherever understanding of the mechanism of neurotransmitter uptake is valuable.
Export Options
About this article
Cite this article as:
Simon Agnes, Bencsura Akos, Heja Laszlo, Magyar Csaba and Kardos Julianna, Sodium-Assisted Formation of Binding and Traverse Conformations of the Substrate in a Neurotransmitter Sodium Symporter Model, Current Drug Discovery Technologies 2014; 11 (3) . https://dx.doi.org/10.2174/1570163811666140812110735
DOI https://dx.doi.org/10.2174/1570163811666140812110735 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Silico Approaches Towards the Understanding of the Structure- Function Relationships in Metabotropic Glutamate Receptors (mGluRs) and other Family C GPRCs
Current Pharmaceutical Design Serotonin as a Modulator of Glutamate- and GABA-Mediated Neurotransmission: Implications in Physiological Functions and in Pathology
Current Neuropharmacology Biology of Heme: Drug Interactions and Adverse Drug Reactions with CYP450
Current Topics in Medicinal Chemistry Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Decreased Valproate Level Caused by VPA-glucuronidase Inhibition by Carbapenem Antibiotics
Drug Metabolism Letters Antiepileptic Activity of Novel 2-(substituted benzylidene)-7-(4- fluorophenyl)-5-(furan-2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one Derivatives
Letters in Drug Design & Discovery Controlling the Flow of Energy: Inhibition and Stimulation of the Creatine Transporter
Current Enzyme Inhibition Stopping Drug Therapy in Epilepsy
Current Pharmaceutical Design Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Old Weapons for New Wars: Bioactive Molecules From Cnidarian Internal Defense Systems
Central Nervous System Agents in Medicinal Chemistry Pharmacological Targeting in Inherited Arrhythmia Syndromes
Current Medicinal Chemistry Finding the Smoking Gun: Protein Tyrosine Phosphatases as Tools and Targets of Unicellular Microorganisms and Viruses
Current Medicinal Chemistry Peptidyl Arginine Deiminases and Neurodegenerative Diseases
Current Medicinal Chemistry Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Current Alzheimer Research Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Role of Vitamins in Neurodegenerative Diseases: A Review
CNS & Neurological Disorders - Drug Targets Therapeutic Monitoring of Carbamazepine in Epilepsy Patients by Highly Sensitive LC/MS Method and its Clinical Applications
Current Analytical Chemistry Recent Advances in the Treatment of Amyotrophic Lateral Sclerosis. Emphasis on Kynurenine Pathway Inhibitors
Central Nervous System Agents in Medicinal Chemistry Safety and Efficacy of Melatonin in Pediatric Migraine Prophylaxis
Current Drug Safety Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design